Leerink Partnrs Issues Negative Estimate for enGene Earnings

enGene Holdings Inc. (NASDAQ:ENGN) – Stock analysts at Leerink Partnrs dropped their FY2029 earnings per share (EPS) estimates for enGene in a research note issued on Wednesday, January 22nd. Leerink Partnrs analyst M. Foroohar now anticipates that the company will post earnings per share of $0.57 for the year, down from their prior forecast of $0.60. The consensus estimate for enGene’s current full-year earnings is ($1.57) per share.

enGene (NASDAQ:ENGN) last released its quarterly earnings results on Thursday, December 19th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.06.

A number of other equities research analysts have also weighed in on the company. HC Wainwright began coverage on enGene in a report on Monday, December 23rd. They issued a “buy” rating and a $25.00 price objective on the stock. Citizens Jmp raised enGene to a “strong-buy” rating in a report on Monday, November 18th. Raymond James began coverage on enGene in a report on Wednesday, November 27th. They issued an “outperform” rating and a $23.00 price objective on the stock. Finally, JMP Securities reaffirmed a “market outperform” rating and issued a $18.00 price objective on shares of enGene in a report on Monday, December 23rd. Ten research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $29.78.

enGene Price Performance

Shares of ENGN opened at $7.16 on Thursday. enGene has a twelve month low of $4.42 and a twelve month high of $18.40. The stock’s 50 day moving average is $7.37 and its two-hundred day moving average is $7.54. The firm has a market capitalization of $316.62 million, a PE ratio of -12.34 and a beta of -0.65. The company has a current ratio of 16.87, a quick ratio of 16.87 and a debt-to-equity ratio of 0.08.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of ENGN. Wolverine Asset Management LLC acquired a new position in shares of enGene during the 3rd quarter worth approximately $37,000. Point72 Asset Management L.P. raised its position in shares of enGene by 1,410.3% during the 3rd quarter. Point72 Asset Management L.P. now owns 663,000 shares of the company’s stock worth $4,376,000 after purchasing an additional 619,100 shares during the last quarter. Finally, Franklin Resources Inc. raised its position in shares of enGene by 48.7% during the 3rd quarter. Franklin Resources Inc. now owns 1,189,952 shares of the company’s stock worth $7,854,000 after purchasing an additional 389,918 shares during the last quarter. 64.16% of the stock is currently owned by institutional investors and hedge funds.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.